EUVIMEDEUVIMED entdecken
Open Access

Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus

Richard A Adeleke iD, Julie Sahler iD, Annette Choi iD, Kyle Roth iD, Viraj Upadhye iD, Shahrzad Ezzatpour iD, Brian Imbiakha iD, Solomiia Khomandiak iD, Annika Diaz, Gary R Whittaker iD, Mason C Jager iD, Avery August iD und 2 weitere

Science Advances · 2025

DOI: 10.1126/sciadv.adq4545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Richard A Adeleke und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Cornell University College of Veterinary Medicine, Ithaca, NY 14853, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, COVID-19 Vaccines, Influenza Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses lead to severe respiratory illnesses and death in humans, exacerbated in individuals with underlying health conditions, remaining substantial global public health concerns. Here, we developed a bivalent replication-incompetent single-cycle pseudotyped vesicular stomatitis virus vaccine that incorporates both a prefusion-stabilized SARS-CoV-2 spike protein lacking a furin cleavage site and a full-length influenza A virus neuraminidase protein. Vaccination of K18-hACE2 or C57BL/6J mouse models generated durable levels of neutralizing antibodies, T cell responses, and protection from morbidity and mortality upon challenge with either virus. Furthermore, the vaccine provided heterologous protection upon challenge with a different influenza virus strain, supporting the advantage of using NA to increase the breadth of vaccine protection. Now, no bivalent vaccine is approved for use against both SARS-CoV-2 and influenza virus. Our study supports using this platform to develop safe and efficient vaccines against multiple viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19COVID-19 VaccinesInfluenza VaccinesOrthomyxoviridae InfectionsAnimalsMiceMice, Inbred C57BLHumansSpike Glycoprotein, CoronavirusAntibodies, ViralAntibodies, NeutralizingFemaleNeuraminidaseVirus ReplicationInfluenza A virus

Substanzen

Spike Glycoprotein, CoronavirusAntibodies, ViralAntibodies, NeutralizingCOVID-19 VaccinesInfluenza VaccinesNeuraminidasespike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Cornell University College of Veterinary Medicine, Ithaca, NY 14853, USA.
  • Department of Population Medicine and Diagnostic Sciences, Cornell University College of Veterinary Medicine, Ithaca, NY 14853, USA.

ORCID-Profile: Richard A Adeleke, Julie Sahler, Annette Choi, Kyle Roth, Viraj Upadhye, Shahrzad Ezzatpour, Brian Imbiakha, Solomiia Khomandiak, Gary R Whittaker, Mason C Jager, Avery August, David W Buchholz, Hector C Aguilar

Förderung

  • NIAID NIH HHS

Zitieren

APA

Adeleke, R. A., Sahler, J., Choi, A., Roth, K., Upadhye, V., Ezzatpour, S., Imbiakha, B., Khomandiak, S., Diaz, A., Whittaker, G. R., Jager, M. C., August, A., Buchholz, D. W., & Aguilar, H. C. (2025). Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus. Science Advances. https://doi.org/10.1126/sciadv.adq4545

Vancouver

Adeleke RA, Sahler J, Choi A, Roth K, Upadhye V, Ezzatpour S, et al. Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus. Science Advances. 2025. doi:10.1126/sciadv.adq4545

BibTeX
@article{Adeleke2025,
  author = {Adeleke, Richard A and Sahler, Julie and Choi, Annette and Roth, Kyle and Upadhye, Viraj and Ezzatpour, Shahrzad and Imbiakha, Brian and Khomandiak, Solomiia and Diaz, Annika and Whittaker, Gary R and Jager, Mason C and August, Avery and Buchholz, David W and Aguilar, Hector C},
  title = {Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adq4545}
}
Kostenlos starten →